FABP1: A Potential Drug Target and Biomarker for Fatty Acid Binding Protein 1 in Human Liver

Target Name: FABP1

NCBI ID: G2168

FABP1

FABP1: A Potential Drug Target and Biomarker for Fatty Acid Binding Protein 1 in Human Liver

Abstract:

Fatty acid binding protein 1 (FABP1) is a liver-enriched protein that has been identified as a potential drug target and biomarker for various diseases, including fatty liver diseases. This protein plays a crucial role in the regulation of lipid metabolism and has been implicated in the development and progression of several diseases, including obesity, nonalcoholic steatohepatitis (NASH), and cardiovascular diseases.

FABP1 is a member of the fatty acid binding protein (FABP) family, which includes several similar proteins that share a conserved catalytic core and a N-terminal transmembrane region. These proteins are characterized by their ability to bind fatty acids and modulate lipid metabolism, including the transport, storage, and metabolism of triacylglycerols (triglycerides) in adipose tissue and the liver.

Expression and localization of FABP1 are highly sensitive to changes in membrane phospholipid composition and disruptions in the balance between fatty acid and chylomicron content. This protein has been shown to play a critical role in the regulation of lipid metabolism and the pathogenesis of various diseases, including NASH, obesity, and cardiovascular diseases.

FABP1 has been identified as a potential drug target due to its unique structure and its involvement in the regulation of lipid metabolism. Several studies have demonstrated that inhibiting FABP1 activity can improve lipid profiles and reduce the risk of developing NASH and other diseases associated with obesity and metabolic disorders.

In addition to its potential therapeutic applications, FABP1 has also been shown to be a valuable biomarker for the diagnosis and monitoring of NASH and other diseases associated with obesity and metabolic disorders. Several studies have shown that FABP1 levels are elevated in individuals with NASH and that inhibiting FABP1 activity can improve the severity and persistence of NASH symptoms.

FABP1 has been localized to various tissues and organs, including liver, adipose tissue, and blood vessels. Localization studies have shown that FABP1 is primarily expressed in the liver and adipose tissue, with lower levels observed in other tissues. This localization suggests that FABP1 may have a specific role in modulating lipid metabolism in these tissues and that it may be a useful biomarker for the diagnosis and monitoring of diseases associated with obesity and metabolic disorders.

In conclusion, FABP1 is a promising drug target and biomarker for the regulation of lipid metabolism and the development of various diseases associated with obesity and metabolic disorders. Further research is needed to fully understand the role of FABP1 in modulating lipid metabolism and to develop effective therapies that target this protein.

Keywords: Fatty acid binding protein 1, drug target, biomarker, lipid metabolism, obesity, NASH, cardiovascular diseases

Protein Name: Fatty Acid Binding Protein 1

Functions: Plays a role in lipoprotein-mediated cholesterol uptake in hepatocytes (PubMed:25732850). Binds cholesterol (PubMed:25732850). Binds free fatty acids and their coenzyme A derivatives, bilirubin, and some other small molecules in the cytoplasm. May be involved in intracellular lipid transport (By similarity)

The "FABP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FABP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets